http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H04282314-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24a14cc1ad3881d897b18482a3289502 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C225-24 |
| filingDate | 1991-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a94b4b0a6617ad2f013d5031593c9b62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e175102a804d83fb78821da9405d49ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7edc2cefd3a0f6c1a208238e0f66805 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e5e7dcd3eeb45ddbd2d588be1a859b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9d8742a4359a07d0f62da75f9a1c4a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a93e8470b32369f37712db92f54376f9 |
| publicationDate | 1992-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H04282314-A |
| titleOfInvention | Agent for improving cerebral function |
| abstract | PURPOSE: To obtain a cerebral function improving agent, especially a therapeutic agent for sequela of cerebral apoplexy by using a specific 3-amino-2- cyclohexenone derivative as an active component. n CONSTITUTION: The objective cerebral ischemia improving agent contains a compound of formula (R 1 and R 2 are H, halogen, CN, NO 2 or 1-3C alkoxy; R 3 to R 5 are H or methyl; preferably R 1 is halogen and R 2 is H or halogen, R 1 is NO 2 and R 2 is H, NO 2 or halogen, R 1 is CN and R 2 is H, CN or halogen, all of R 1 to R 3 are H, or R 3 is H and R 4 and R 5 are methyl) as an active component. The compound prolongs the survival time under hypoxic load and the survival time to KCN death and exhibits considerable effect to cerebral ischemia. The cerebral ischemia improving agent can be administered by proper methods such as oral or parenteral administration. The daily dose of the above compound for adult is 5-500mg (preferably 5-50mg) for oral administration and 1-100mg (preferably 1-10mg) for parenteral administration. n COPYRIGHT: (C)1992,JPO&Japio |
| priorityDate | 1991-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.